The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some safety setbacks and years of generic competition, Takeda is calling it quits ...
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...
DelveInsight's“Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted ...
High Blood Pressure has become a major public health concern in recent times. Research into natural remedies for health ...
Zacks.com on MSN14h
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth NowAccording to our calculations, a $1000 investment made in January 2015 would be worth $4,020.91, or a gain of 302.09%, as of January 27, 2025, and this return excludes dividends but includes price ...
Hosted on MSN6h
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the WorldAscentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...
GlobalData on MSN6d
Health Canada gives Takeda’s mCRC capsules market authorisationHealth Canada has granted market authorisation to Takeda Canada for FRUZAQLA (fruquintinib) capsules to treat adults with ...
Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.
Brown & Brown's fourth-quarter revenue beat analyst expectations as commissions and fees rose. The insurance company said profit fell to $210 million from $269 million a year earlier, though adjusted ...
buying a portfolio of drugs including diabetes and hypertension drugs from Takeda that will expand its expertise with small molecule drugs. Celltrion has made its name by producing ...
Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback